HUS2100027I1 - Tisztított aktív polipeptidek és immunkonjugátumok - Google Patents
Tisztított aktív polipeptidek és immunkonjugátumokInfo
- Publication number
- HUS2100027I1 HUS2100027I1 HUS2100027C HUS2100027C HUS2100027I1 HU S2100027 I1 HUS2100027 I1 HU S2100027I1 HU S2100027 C HUS2100027 C HU S2100027C HU S2100027 C HUS2100027 C HU S2100027C HU S2100027 I1 HUS2100027 I1 HU S2100027I1
- Authority
- HU
- Hungary
- Prior art keywords
- immunoconjugates
- active polypeptides
- purified active
- purified
- polypeptides
- Prior art date
Links
- 229940127121 immunoconjugate Drugs 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
- B01D15/16—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the fluid carrier
- B01D15/166—Fluid composition conditioning, e.g. gradient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
- B01D15/361—Ion-exchange
- B01D15/363—Anion-exchange
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J41/00—Anion exchange; Use of material as anion exchangers; Treatment of material for improving the anion exchange properties
- B01J41/08—Use of material as anion exchangers; Treatment of material for improving the anion exchange properties
- B01J41/12—Macromolecular compounds
- B01J41/14—Macromolecular compounds obtained by reactions only involving unsaturated carbon-to-carbon bonds
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J41/00—Anion exchange; Use of material as anion exchangers; Treatment of material for improving the anion exchange properties
- B01J41/20—Anion exchangers for chromatographic processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Inorganic Chemistry (AREA)
- Endocrinology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36914810P | 2010-07-30 | 2010-07-30 | |
| EP18174165.3A EP3434346B1 (en) | 2010-07-30 | 2011-07-27 | Purified active polypeptides or immunoconjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUS2100027I1 true HUS2100027I1 (hu) | 2021-07-28 |
Family
ID=45530485
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE18174165A HUE051702T2 (hu) | 2010-07-30 | 2011-07-27 | Tisztított aktív polipeptidek és immunkonjugátumok |
| HUS2100027C HUS2100027I1 (hu) | 2010-07-30 | 2021-07-14 | Tisztított aktív polipeptidek és immunkonjugátumok |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE18174165A HUE051702T2 (hu) | 2010-07-30 | 2011-07-27 | Tisztított aktív polipeptidek és immunkonjugátumok |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US9580461B2 (hu) |
| EP (3) | EP2613857B1 (hu) |
| JP (1) | JP6061853B2 (hu) |
| CN (1) | CN103079666B (hu) |
| BR (1) | BR112013002334A2 (hu) |
| CA (1) | CA2806314C (hu) |
| DK (1) | DK3434346T3 (hu) |
| ES (2) | ES2678204T3 (hu) |
| HU (2) | HUE051702T2 (hu) |
| LT (2) | LT3434346T (hu) |
| MX (1) | MX342920B (hu) |
| NO (1) | NO2021030I1 (hu) |
| PL (1) | PL3434346T3 (hu) |
| PT (1) | PT3434346T (hu) |
| SG (3) | SG10202009967TA (hu) |
| WO (1) | WO2012015912A1 (hu) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101134146B1 (ko) * | 2010-05-31 | 2012-04-19 | 메덱스젠 주식회사 | 국소 근마비 효과를 갖는 비확산형 보툴리눔 독소와 그의 정제방법 |
| JP6061853B2 (ja) | 2010-07-30 | 2017-01-18 | メディミューン,エルエルシー | 活性ポリペプチドまたは免疫複合体の精製方法 |
| JP2013540157A (ja) * | 2010-10-20 | 2013-10-31 | メディミューン,エルエルシー | 封入体を処理する方法 |
| CN104507955A (zh) | 2012-05-31 | 2015-04-08 | 新加坡科技研究局 | 采用具有多形式官能性的颗粒对免疫球蛋白g制备物的色谱纯化 |
| EP2934597B1 (en) * | 2012-12-20 | 2018-10-17 | MedImmune, LLC | Methods of producing immunoconjugates |
| GB201412658D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
| KR101531479B1 (ko) * | 2014-11-21 | 2015-06-26 | 세원셀론텍(주) | 의료용 재료로 사용하기 위한 고농도 콜라겐 제조방법 |
| CN108472360B (zh) * | 2015-04-10 | 2023-01-17 | 阿迪马布有限责任公司 | 从亲代同源二聚抗体种类中纯化异源二聚多特异性抗体的方法 |
| GB201601075D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies molecules |
| GB201601073D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies |
| GB201601077D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibody molecule |
| TW202247855A (zh) | 2016-09-13 | 2022-12-16 | 美商愛力根公司 | 非蛋白梭菌毒素組成物 |
| WO2018075357A1 (en) * | 2016-10-17 | 2018-04-26 | Duke University | PRODUCTION OF IMMUNOTOXIN D2C7-(scdsFv)-PE38KDEL |
| SG10201912529SA (en) | 2016-11-18 | 2020-02-27 | Astellas Pharma Inc | Novel anti-human muc1 antibody fab fragment |
| US11174284B2 (en) * | 2017-04-04 | 2021-11-16 | Scarab Genomics, Llc | Purification of CRM 197 from bacteria |
| TWI795415B (zh) | 2017-07-07 | 2023-03-11 | 日商安斯泰來製藥股份有限公司 | 新穎的抗人類CEACAM5抗體Fab片段 |
| US11198722B2 (en) | 2017-10-06 | 2021-12-14 | University Of Utah Research Foundation | Immune tolerant elastin-like peptide tetramer guided nanoparticles and methods of use |
| US20200239575A1 (en) * | 2017-10-06 | 2020-07-30 | University Of Utah Research Foundation | A fusion protein for targeted therapy of autoimmune disease |
| CA3100317A1 (en) | 2018-05-17 | 2019-11-21 | Astellas Pharma Inc. | Complex having anti-human muc1 antibody fab fragment, peptide linker and/or ligand |
| CN112839683B (zh) * | 2018-10-10 | 2023-11-14 | 安斯泰来制药株式会社 | 含有标记部-抗人抗体Fab片段复合物的药物组合物 |
| US12514927B2 (en) | 2019-10-30 | 2026-01-06 | Duke University | Immunotherapy with combination therapy comprising an immunotoxin |
| EP4103938A1 (en) | 2020-02-13 | 2022-12-21 | F. Hoffmann-La Roche AG | Method for determining the loading state of an aav particle by nuclear magnetic resonance relaxometry |
| EP4175969A4 (en) * | 2020-07-01 | 2024-07-24 | Medimmune, LLC | DETERGENT AND METHOD FOR PURIFYING A BIOTHERAPY AGENT |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3060165A (en) | 1962-10-23 | Preparation of toxic ricin | ||
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5079163A (en) | 1985-03-29 | 1992-01-07 | Cetus Corporation | Recombinant ricin toxin fragments |
| US4689401A (en) | 1986-03-06 | 1987-08-25 | Cetus Corporation | Method of recovering microbially produced recombinant ricin toxin a chain |
| US4892827A (en) | 1986-09-24 | 1990-01-09 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects |
| EP0531434B1 (en) | 1990-05-11 | 1999-07-14 | THE UNITED STATES OF AMERICA as represented by the Secretary UNITED STATES DEPARTMENT OF COMMERCE | Improved pseudomonas exotoxins of low animal toxicity and high cytocidal activity |
| US5608039A (en) | 1990-10-12 | 1997-03-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Single chain B3 antibody fusion proteins and their uses |
| CA2136724A1 (en) | 1992-06-18 | 1993-12-23 | Ira H. Pastan | Recombinant pseudomonas exotoxin with increased activity |
| ES2300122T3 (es) | 1997-03-20 | 2008-06-01 | The Government Of The Usa As Represented By The Secretary Of Department Of Health And Human Services | Anticuerpos recombinantes e inmunoconjugados dirigidos contra celulas y tumores portadores de cd-22. |
| US6296843B1 (en) | 1998-04-03 | 2001-10-02 | The Penn State Research Foundation | Mutagenized IL 13-based chimeric molecules |
| US7355012B2 (en) | 2001-09-26 | 2008-04-08 | United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Mutated anti-CD22 antibodies with increased affinity to CD22-expressing leukemia cells |
| WO2003051926A2 (en) * | 2001-12-14 | 2003-06-26 | Friedrich-Alexander-Universitaet Erlangen-Nuernberg | Anti-cd7 immunotoxin as fusion protein |
| JP2004089182A (ja) * | 2002-06-24 | 2004-03-25 | Takeda Chem Ind Ltd | がんの予防・治療剤 |
| CA2496060C (en) * | 2002-09-11 | 2015-08-04 | Genentech, Inc. | Protein purification by ion exchange chromatography |
| AU2004293471C1 (en) * | 2003-11-25 | 2011-02-24 | The Government Of The United States, As Represented By The Secretary Of Health And Human Services | Mutated anti-CD22 antibodies and immunoconjugates |
| US20080125363A1 (en) * | 2004-12-14 | 2008-05-29 | Enzon Pharmaceuticals Inc. | Polymer-Linked Pseudomonas Exotoxin Immunotoxin |
| PL3006457T3 (pl) | 2005-07-29 | 2018-05-30 | The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Services | Zmutowane egzotoksyny Pseudomonas o zmniejszonej antygenowości |
| CA2663892A1 (en) * | 2006-09-25 | 2008-04-03 | Medimmune, Llc | Stabilized antibody formulations and uses thereof |
| CN101541345A (zh) * | 2006-09-25 | 2009-09-23 | 米迪缪尼有限公司 | 稳定化的抗体制剂和其应用 |
| PL2197903T3 (pl) | 2007-09-04 | 2015-03-31 | Us Gov Health & Human Services | Delecje w domenie ii egzotoksyny a psuedomonas zmniejszające toksyczność niespecyficzną |
| WO2009149281A1 (en) * | 2008-06-04 | 2009-12-10 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Immunotoxins and uses thereof |
| JP5836125B2 (ja) * | 2008-10-16 | 2015-12-24 | ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | 高分子量メラノーマ関連抗原に対する完全ヒト抗体およびその使用 |
| JP6061853B2 (ja) | 2010-07-30 | 2017-01-18 | メディミューン,エルエルシー | 活性ポリペプチドまたは免疫複合体の精製方法 |
-
2011
- 2011-07-27 JP JP2013521934A patent/JP6061853B2/ja not_active Expired - Fee Related
- 2011-07-27 HU HUE18174165A patent/HUE051702T2/hu unknown
- 2011-07-27 CN CN201180037262.XA patent/CN103079666B/zh not_active Expired - Fee Related
- 2011-07-27 SG SG10202009967TA patent/SG10202009967TA/en unknown
- 2011-07-27 EP EP11813105.1A patent/EP2613857B1/en active Active
- 2011-07-27 CA CA2806314A patent/CA2806314C/en active Active
- 2011-07-27 PL PL18174165T patent/PL3434346T3/pl unknown
- 2011-07-27 SG SG10201506030RA patent/SG10201506030RA/en unknown
- 2011-07-27 ES ES11813105.1T patent/ES2678204T3/es active Active
- 2011-07-27 SG SG2013005228A patent/SG187587A1/en unknown
- 2011-07-27 BR BR112013002334A patent/BR112013002334A2/pt not_active IP Right Cessation
- 2011-07-27 ES ES18174165T patent/ES2836447T3/es active Active
- 2011-07-27 US US13/813,083 patent/US9580461B2/en not_active Expired - Fee Related
- 2011-07-27 EP EP18174165.3A patent/EP3434346B1/en active Active
- 2011-07-27 EP EP20192591.4A patent/EP3797847A1/en not_active Withdrawn
- 2011-07-27 WO PCT/US2011/045524 patent/WO2012015912A1/en not_active Ceased
- 2011-07-27 MX MX2013001044A patent/MX342920B/es active IP Right Grant
- 2011-07-27 LT LTEP18174165.3T patent/LT3434346T/lt unknown
- 2011-07-27 PT PT181741653T patent/PT3434346T/pt unknown
- 2011-07-27 DK DK18174165.3T patent/DK3434346T3/da active
-
2017
- 2017-02-03 US US15/423,928 patent/US10072083B2/en active Active
-
2018
- 2018-09-07 US US16/124,441 patent/US10556955B2/en not_active Expired - Fee Related
-
2020
- 2020-02-10 US US16/786,634 patent/US11136396B2/en not_active Expired - Fee Related
-
2021
- 2021-07-14 HU HUS2100027C patent/HUS2100027I1/hu unknown
- 2021-07-15 NO NO2021030C patent/NO2021030I1/no unknown
- 2021-07-29 LT LTPA2021517C patent/LTPA2021517I1/lt unknown
- 2021-09-02 US US17/465,092 patent/US20210395370A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS2100027I1 (hu) | Tisztított aktív polipeptidek és immunkonjugátumok | |
| GB201010193D0 (en) | Medicinal use | |
| ZA201300194B (en) | Formulations | |
| HRP20141173T1 (hr) | Medikament koji sadrži miramistin | |
| GB201110193D0 (en) | Formulations | |
| GB201013513D0 (en) | Formulations | |
| ZA201300196B (en) | Formulations | |
| GB201007217D0 (en) | The carrying assistant | |
| GB201020156D0 (en) | The active doorstep-cowie | |
| GB201012046D0 (en) | Pharmaceutical formulations | |
| GB201012047D0 (en) | Pharmaceutical formulations | |
| TWM387625U (en) | Improved bedpan | |
| TWM401439U (en) | Improved urn structure | |
| TWM400848U (en) | Improved urn structure | |
| TWM400847U (en) | Cinerary urn | |
| HUP1000034D0 (en) | Novel pharmaceutical agents | |
| GB201000492D0 (en) | K&Rimp | |
| GB201005838D0 (en) | The tie right | |
| ZA201301851B (en) | Pharmaceutical combinations | |
| GB201001317D0 (en) | Medicament | |
| GB201010494D0 (en) | Formulations | |
| GB201018648D0 (en) | Formulations | |
| GB201018649D0 (en) | Formulations | |
| GB201018647D0 (en) | Formulations | |
| GB201018645D0 (en) | Formulations |